These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37108147)

  • 81. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
    Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
    Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis.
    Lei JH; Liu LR; Wei Q; Song TR; Yang L; Meng Y; Han P
    Asian J Androl; 2016; 18(1):102-7. PubMed ID: 25851657
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
    J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.
    Cowan BA; Olivier K; Tombal B; Wefel JS
    Adv Ther; 2024 Feb; 41(2):476-491. PubMed ID: 37979089
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer.
    Fradin J; Kim FJ; Lu-Yao GL; Storozynsky E; Kelly WK
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190244
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
    Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
    Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
    Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
    Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.
    Chen QH
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444418
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials.
    Zhuang J; Wang Y; Zhang S; Fu Y; Huang H; Lyu X; Zhang S; Marra G; Xu L; Qiu X; Guo H
    Front Pharmacol; 2023; 14():1217303. PubMed ID: 37435500
    [No Abstract]   [Full Text] [Related]  

  • 95. The role of 11-oxygenated androgens in prostate cancer.
    Snaterse G; Hofland J; Lapauw B
    Endocr Oncol; 2023 Jan; 3(1):e220072. PubMed ID: 37434644
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Validation of JSBMR's CTIBL manual for Japanese men receiving androgen deprivation therapy for prostate cancer.
    Matsushima H
    J Bone Miner Metab; 2023 Nov; 41(6):822-828. PubMed ID: 37498323
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Nowakowska MK; Ortega RM; Wehner MR; Nead KT
    JAMA Oncol; 2023 Jul; 9(7):930-937. PubMed ID: 37227736
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.
    Fukuokaya W; Mori K; Yanagisawa T; Akazawa K; Shimomura T; Kimura T
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):444-450. PubMed ID: 37464102
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
    Crabb S; Morgan A; Hunter MS; Stefanopoulou E; Griffiths G; Richardson A; Fenlon D; Fleure L; Raftery J; Boxall C; Wilding S; Nuttall J; Eminton Z; Tilt E; O'Neill A; Bacon R; Martin J
    Trials; 2023 Jul; 24(1):450. PubMed ID: 37430353
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.
    Vanden Berg RNW; Zilli T; Achard V; Dorff T; Abern M
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):702-711. PubMed ID: 37422523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.